Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Cysic Cysic +22.50%
#4 Bedrock Bedrock +19.73%
#5 Velvet Velvet +19.00%
#6 Fabric Protocol Fabric Protocol +16.39%
#7 Nockchain Nockchain +16.19%
#8 Perle Perle +13.72%
#9 Versatize Coin Versatize Coin +12.49%
#10 Starpower Starpower +12.07%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Amniotics AB (publ) Amniotics AB (publ)

Amniotics AB (publ)

AMNI
Rank in Stocks #37511
Amniotics AB (publ) specializes in the creation, manufacturing, and... Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Share Price
$0.00060315
Last synced: 2024-09-27
Market Cap
$1.65M
Change (1 day)
19.64%
Change (1 year)
0.00%
Country
SE
Trade Amniotics AB (publ) (AMNI)

Category

Healthcare
P/E ratio for Amniotics AB (publ) (AMNI)
P/E ratio as of August 2026 TTM: -0.49
According to Amniotics AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.49. At the end of 2022 the company had a P/E ratio of -1.31.
P/E ratio history for Amniotics AB (publ) from 2018 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.49 -40.13%
2023 -0.82 -37.68%
2022 -1.31 -88.17%
2021 -11.10 -55.21%
2020 -24.78 -66.36%
2019 -73.65 -34.23%
2018 -111.99 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -6,048.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -6,337.36%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -3,844.35%
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.